New England Journal of Medicine
The FOCUS trial — a major RCT of 2,016 patients — demonstrated that a restrictive transfusion strategy (hemoglobin trigger of 8 g/dL) was not inferior to a liberal strategy (10 g/dL) for mortality or functional recovery after hip fracture surgery.